Literature DB >> 7969494

Specific incorporation of cyclophilin A into HIV-1 virions.

E K Franke1, H E Yuan, J Luban.   

Abstract

Little is known about host factors necessary for retroviral virion assembly or uncoating. We have previously shown that the principal structural protein of the human immunodeficiency virus HIV-1, the Gag polyprotein, binds the cyclophilin peptidyl-prolyl isomerases; cyclophilins catalyse a rate-limiting step in protein folding and protect cells from heat shock. Here we demonstrate that cyclophilin A is specifically incorporated into HIV-1 virions but not into virions of other primate immunodeficiency viruses. A proline-rich region conserved in all HIV-1 Gag polyproteins is required for cyclophilin A binding and incorporation. Disruption of a single proline blocks the Gag-cyclophilin interaction in vitro, prevents cyclophilin A incorporation into virions, and inhibits HIV-1 replication. Our results indicate that the interaction of Gag with cyclophilin A is necessary for the formation of infectious HIV-1 virions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7969494     DOI: 10.1038/372359a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  310 in total

1.  Mass determination of rous sarcoma virus virions by scanning transmission electron microscopy.

Authors:  V M Vogt; M N Simon
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

2.  Role for human immunodeficiency virus type 1 Tat protein in suppression of viral reverse transcriptase activity during late stages of viral replication.

Authors:  M Kameoka; L Rong; M Götte; C Liang; R S Russell; M A Wainberg
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

3.  HIV-1 Gag shares a signature motif with annexin (Anx7), which is required for virus replication.

Authors:  M Srivastava; M Cartas; T A Rizvi; S P Singh; D Serio; V S Kalyanaraman; H B Pollard; A Srinivasan
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

4.  Head-to-tail dimers and interdomain flexibility revealed by the crystal structure of HIV-1 capsid protein (p24) complexed with a monoclonal antibody Fab.

Authors:  C Berthet-Colominas; S Monaco; A Novelli; G Sibaï; F Mallet; S Cusack
Journal:  EMBO J       Date:  1999-03-01       Impact factor: 11.598

5.  Human immunodeficiency virus type 1 N-terminal capsid mutants that exhibit aberrant core morphology and are blocked in initiation of reverse transcription in infected cells.

Authors:  S Tang; T Murakami; B E Agresta; S Campbell; E O Freed; J G Levin
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

6.  CD147 facilitates HIV-1 infection by interacting with virus-associated cyclophilin A.

Authors:  T Pushkarsky; G Zybarth; L Dubrovsky; V Yurchenko; H Tang; H Guo; B Toole; B Sherry; M Bukrinsky
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

7.  Structural consequences of cyclophilin A binding on maturational refolding in human immunodeficiency virus type 1 capsid protein.

Authors:  L Dietrich; L S Ehrlich; T J LaGrassa; D Ebbets-Reed; C Carter
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

8.  Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A.

Authors:  C Aiken
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

9.  Structure of the immature HIV-1 capsid in intact virus particles at 8.8 Å resolution.

Authors:  Florian K M Schur; Wim J H Hagen; Michaela Rumlová; Tomáš Ruml; Barbara Müller; Hans-Georg Kräusslich; John A G Briggs
Journal:  Nature       Date:  2014-11-02       Impact factor: 49.962

10.  Role for human immunodeficiency virus type 1 membrane cholesterol in viral internalization.

Authors:  Mireille Guyader; Etsuko Kiyokawa; Laurence Abrami; Priscilla Turelli; Didier Trono
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.